RPRD1B promotes tumor growth by accelerating the cell cycle in endometrial cancer

Oncology Reports

Volumn 31, Issue 3, 2014, Pages 1389-1395

  Wang, Yuan ^a   Qiu, Haifeng ^b   Hu, Weixu ^c   Li, Shaoru ^d   Yu, Jinjin ^a  

^a JIANGNAN UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

^c FUDAN UNIVERSITY   (China)

^d XINXIANG MEDICAL UNIVERSITY   (China)

Author keywords

Cell cycle; Cell proliferation; Endometrial cancer; RPRD1B; Tumor growth

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER STAGING; CELL CYCLE ARREST; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; ENDOMETRIUM CANCER; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE OVEREXPRESSION; GENE SILENCING; GENE TARGETING; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MITOSIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RNA GENE; RPRD1B GENE; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, ENDOMETRIOID; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; ENDOMETRIAL NEOPLASMS; FEMALE; G1 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION; HUMANS; INHIBITORY CONCENTRATION 50; LYMPHATIC METASTASIS; MICE; MICE, SCID; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; RALOXIFENE; TUMOR BURDEN; UP-REGULATION;

EID: 84896726219     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.2990     Document Type: Article

References (28)

1. Wei KR, Chen WQ, Zhang SW, Zheng RS, Wang YN and Liang ZH: Epidemiology of uterine corpus cancer in some cancer registering areas of China from 2003-2007. Zhonghua Fu Chan Ke Za Zhi 47: 445-451, 2013 (In Chinese).
2. Jamison PM, Noone AM, Ries LA, Lee NC and Edwards BK: Trends in endometrial cancer incidence by race and histology with a correction for the prevalence of hysterectomy, SEER 1992 to 2008. Cancer Epidemiol Biomarkers Prev 22: 233-241, 2013.
3. Bray F, Dos Santos Silva I, Moller H and Weiderpass E: Endometrial cancer incidence trends in Europe: underlying determinants and prospects for prevention. Cancer Epidemiol Biomarkers Prev 14: 1132-1142, 2005. (Pubitemid 40656458)
4. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63: 11-30, 2013.
5. Hecht JL and Mutter GL: Molecular and pathologic aspects of endometrial carcinogenesis. J Clin Oncol 24: 4783-4791, 2006. (Pubitemid 46630943)
6. Dedes KJ, Wetterskog D, Ashworth A, Kaye SB and Reis-Filho JS: Emerging therapeutic targets in endometrial cancer. Nat Rev Clin Oncol 8: 261-271, 2011.
7. Bokhman JV: Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 15: 10-17, 1983.
8. Boruta DM II, Gehrig PA, Fader AN and Olawaiye AB: Management of women with uterine papillary serous cancer: a Society of Gynecologic Oncology (SGO) review. Gynecol Oncol 115: 142-153, 2009.
9. Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E and Vergote I: Endometrial cancer. Lancet 366: 491-505, 2005. (Pubitemid 41111699)
10. Saso S, Chatterjee J, Georgiou E, Ditri AM, Smith JR and Ghaem-Maghami S: Endometrial cancer. BMJ 343: d3954, 2011.
11. Del Carmen MG, Boruta DM II and Schorge JO: Recurrent endometrial cancer. Clin Obstet Gynecol 54: 266-277, 2011.
12. Thanapprapasr D and Thanapprapasr K: Molecular therapy as a future strategy in endometrial cancer. Asian Pac J Cancer Prev 14: 3419-3423, 2013.
13. Malumbres M and Barbacid M: Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 9: 153-166, 2009.
14. Lu D, Wu Y, Wang Y, et al: CREPT accelerates tumorigenesis by regulating the transcription of cell-cycle-related genes. Cancer Cell 21: 92-104, 2012.
15. Ni Z, Olsen JB, Guo X, et al: Control of the RNA polymerase II phosphorylation state in promoter regions by CTD interaction domain-containing proteins RPRD1A and RPRD1B. Transcription 2: 237-242, 2011.
16. Creasman W: Revised FIGO staging for carcinoma of the endometrium. Int J Gynaecol Obstet 105: 109, 2009.
17. Kim JK and Diehl JA: Nuclear cyclin D1: an oncogenic driver in human cancer. J Cell Physiol 220: 292-296, 2009.
18. Massague J: G1 cell-cycle control and cancer. Nature 432: 298-306, 2004.
19. Mitselou A, Ioachim E, Zagorianakou N, Kitsiou E, Vougiouklakis T and Agnantis NJ: Expression of the cell-cycle regulatory proteins (cyclins D1 and E) in endometrial carcinomas: correlations with hormone receptor status, proliferating indices, tumor suppressor gene products (p53, pRb), and clinico-pathological parameters. Eur J Gynaecol Oncol 25: 719-724, 2004. (Pubitemid 39576951)
20. Semczuk A and Jakowicki JA: Alterations of pRb1-cyclin D1-cdk4/6-p16(INK4A) pathway in endometrial carcinogenesis. Cancer Lett 203: 1-12, 2004. (Pubitemid 37506078)
21. Horree N, van Diest PJ, Sie-Go DM and Heintz AP: The invasive front in endometrial carcinoma: higher proliferation and associated derailment of cell cycle regulators. Hum Pathol 38: 1232-1238, 2007. (Pubitemid 47058161)
22. Ortega S, Malumbres M and Barbacid M: Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta 1602: 73-87, 2002. (Pubitemid 34311901)
23. Martin A, Odajima J, Hunt SL, et al: Cdk2 is dispensable for cell cycle inhibition and tumor suppression mediated by p27Kip1 and p21Cip1. Cancer Cell 7: 591-598, 2005. (Pubitemid 40799251)
24. Lundberg AS and Weinberg RA: Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol Cell Biol 18: 753-761, 1998. (Pubitemid 28063408)
25. Rane SG, Dubus P, Mettus RV, et al: Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in β-islet cell hyperplasia. Nat Genet 22: 44-52, 1999.
26. Rosu-Myles M, Taylor BJ and Wolff L: Loss of the tumor suppressor p15Ink4b enhances myeloid progenitor formation from common myeloid progenitors. Exp Hematol 35: 394-406, 2007.
27. Brzozowski AM, Pike AC, Dauter Z, et al: Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389: 753-758, 1997. (Pubitemid 27458965)
28. Maximov PY, Lee TM and Jordan VC: The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice. Curr Clin Pharmacol 8: 135-155, 2013.